Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT00606385 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for HCC

HCC
Start date: December 2007
Phase: N/A
Study type: Interventional

Short-term outcomes of laparoscopic liver resection is better than those of open liver resection Laparoscopic liver resection is better than open resection in immunological aspects

NCT ID: NCT00605150 Completed - Clinical trials for Hepatocellular Carcinoma

HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC

Start date: January 2008
Phase:
Study type: Observational

MDS Nordion's TheraSphere, Yttrium-90 glass microspheres has been approved as a Humanitarian device authorized by federal(USA)law for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma(HCC)who can have placement of appropriately positioned hepatic arterial catheters. Outcomes of this treatment protocol will be monitored and reported to the Carolinas HealthCare System Institutional Review Board.

NCT ID: NCT00600522 Completed - Clinical trials for Hepatocellular Carcinoma

Alternative Surgical Policy for Central Liver Tumors

Start date: January 2004
Phase: N/A
Study type: Observational

Major hepatectomies have not negligible morbidity and mortality. However, when tumors invade middle hepatic vein (MHV) at caval confluence major surgery is usually recommended. Ultrasound-guided hepatectomy might allow conservative approaches. We prospectively check its feasibility in a series of patients carriers of tumors invading the MHV at the caval confluence.

NCT ID: NCT00568308 Terminated - Cancer Clinical Trials

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

PATHWAY
Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

NCT ID: NCT00562666 Terminated - Clinical trials for Hepatocellular Carcinoma

Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells

ICAR
Start date: February 2008
Phase: Phase 1
Study type: Interventional

For most patients with hepatocellular carcinoma, surgery or other curative procedures are not possible and only palliative measures could be applied (chemoembolization, targeted drugs, best supportive cares, etc). In the ICAR study, increasing doses of a cell therapy product will be evaluated in patients in a palliative setting. All patients will have one hepatic intra-arterial injection of immunological cells (gamma-delta T lymphocytes) and will be evaluated for safety.

NCT ID: NCT00561522 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection

Start date: November 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.

NCT ID: NCT00557024 Recruiting - Clinical trials for Hepatocellular Carcinoma

Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

RT-RFA
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of the investigators study is to prospectively evaluate whether radiotherapy as an adjuvant therapy after RFA will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC) or not.

NCT ID: NCT00556803 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma

TACE-RFA
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to prospectively evaluate whether transcatheter arterial chemoembolization (TACE) will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC) or not.

NCT ID: NCT00555334 Recruiting - Clinical trials for Hepatocellular Carcinoma

Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma

LAM-RFA
Start date: November 2007
Phase: Phase 4
Study type: Interventional

The purpose of the investigators' study is to prospectively evaluate whether nucleoid antiviral therapy will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC).

NCT ID: NCT00554905 Recruiting - Clinical trials for Hepatocellular Carcinoma

Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma

RFA and TACE
Start date: October 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to prospectively evaluate whether combined RFA and TACE (RFA-TACE) result in better survival outcomes than RFA alone in patients with HCC.